Examkin

Question

Difficulty: MediumImmunologic and Inflammatory Processes

Targeted biologic therapies are foundational in the management of severe rheumatologic, gastrointestinal, and dermatologic autoimmune diseases. The efficacy and safety profile of each agent are intrinsically linked to its specific immunopathologic target. Match each immunomodulating biologic agent with its precise molecular target in the inflammatory cascade.

  • AdalimumabTumor necrosis factor-alpha (TNF-α\alpha)
  • Ustekinumabp40 subunit of IL-12 and IL-23
  • SecukinumabInterleukin-17A (IL-17A)
  • TocilizumabInterleukin-6 (IL-6) receptor
  • AbataceptCD80/CD86 on antigen-presenting cells

Answer

Adalimumab binds to TNF-α\alpha. Ustekinumab binds to the p40 subunit of IL-12 and IL-23. Secukinumab binds to IL-17A. Tocilizumab binds to the IL-6 receptor. Abatacept binds to CD80/CD86 on antigen-presenting cells.
Each biologic agent targets a specific mechanistic node in the inflammatory cascade. Matching them correctly relies on understanding whether they neutralize a circulating cytokine (like Adalimumab, Secukinumab, and Ustekinumab), block a cytokine receptor (like Tocilizumab), or interfere with cellular co-stimulation (like Abatacept).

Step-by-Step Solution

1
Identify the primary mechanism of action for TNF inhibitors.
Adalimumab is recognized as a direct monoclonal antibody against TNF-α\alpha.
TNF-α\alpha is a central cytokine in rheumatoid arthritis and inflammatory bowel disease, which Adalimumab neutralizes.
2
Differentiate the interleukin inhibitors by their specific targets.
Ustekinumab targets IL-12/23 (p40 subunit), Secukinumab targets IL-17A, and Tocilizumab blocks the IL-6 receptor.
Recognizing specific interleukin pathways is necessary for appropriate biologic selection based on the patient's underlying condition (e.g., Secukinumab for ankylosing spondylitis, Ustekinumab for Crohn's/psoriasis, Tocilizumab for giant cell arteritis/rheumatoid arthritis).
3
Identify the mechanism of T-cell co-stimulation blockade.
Abatacept acts as a decoy receptor binding to CD80/CD86.
By binding CD80/CD86 on APCs, Abatacept prevents the 'Signal 2' via CD28 required for full T-cell activation.

Key Concept

The precise molecular targets of biologic disease-modifying antirheumatic drugs (DMARDs) dictate their clinical indications and adverse effect profiles.
Rate this question

Topics

Immunologic and Inflammatory Processes

More questions from this topic